These biotech companies have catalysts ahead.

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with consensus price targets implying gains of up to 384%. These pre-revenue or early-revenue firms carry ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While the tariff saga hit the pharma/biotech industry earlier in the year, the ...

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and ...

Legend Biotech Corporation (NASDAQ:LEGN) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Legend Biotech Corporation (NASDAQ:LEGN) tops our list of the best healthcare stocks ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Recent developments in the Canadian market, such as a decline in unemployment and easing inflation, suggest a cautiously optimistic economic outlook. In this context, penny stocks—typically ...

Moleculin is currently advancing a Phase 3 clinical trial called MIRACLE, evaluating its lead program Annamycin in combination with cytarabine for the treatment of relapsed or refractory acute myeloid ...